ADARx Pharmaceuticals (NASDAQ:ADRX) Director Acquires $27,200,000.00 in Stock

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Simeon George acquired 1,600,000 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the transaction, the director directly owned 5,554,094 shares in the company, valued at $94,419,598. The trade was a 40.46% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

ADARx Pharmaceuticals Stock Performance

Shares of ADARx Pharmaceuticals stock opened at $19.54 on Friday. ADARx Pharmaceuticals, Inc. has a 52-week low of $18.50 and a 52-week high of $23.21.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.